1. Scrip

Roche's IMpower130 Met Co-Primary Endpoints, Lifting ASCO Suspense

 
• By Sten Stovall

Roche said its Phase III IMpower130 study met its co-primary endpoints of overall survival and progression-free survival in the advanced first-line setting for non-squamous lung cancer.

Doctor examining at lungs radiograph x-ray film of patient in operation room. medical concept.
Roche Says Tecentriq In IMpower130 Met OS and PFS Co-Primary Endpoints • Source: Shutterstock

Hoping to further support Tecentriq (atezolizumab) in lung cancer, Roche said its Phase III IMpower130 combo study met its co-primary endpoints of overall survival and progression-free survival, and that the anti-PD-L1 MAb plus chemotherapy helped people with metastaticnon-squamous non-small cell lung cancer (NSCLC) live "significantly longer" compared to chemotherapy alone.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer